+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.

Age: 18Years +All GendersPhase 3
185 locations
W

Actively Recruiting

Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.

Age: 10Years - 17YearsAll GendersPhase 3
81 locations
E

Actively Recruiting

Lung cancer is the leading cause of cancer-related death in the United States, and annual lung cancer screening with low-dose computed tomography LDCT has been shown to reduce mortality. However, many people who are eligible for screening based on U.S. Preventive Services Task Force guidelines do not undergo it. This study evaluates new strategies to improve lung cancer screening uptake among adults aged 50 to 80 with a significant smoking history. Participants will be randomly assigned to either enhanced usual care, which includes an educational brochure, or an intervention called Empower LCSCall. The Empower LCS intervention features patient education, provider notifications, patient reminders, and information about financial and community resources. Those who do not complete screening after the initial intervention may receive additional telephone navigation through the Call program to address barriers and assist with scheduling. Participants complete baseline and follow-up surveys at 4 and 8 months. Researchers will review electronic health records to assess discussions, orders, and completion of lung cancer screening. Some participants will also be invited to a one-time interview about their experiences. The study aims to assess the feasibility, acceptability, and preliminary effectiveness of the intervention to inform future efforts to improve equitable access to lung cancer screening.

Age: 50Years - 80YearsAll GendersPhase Not Applicable
57 locations
E

Actively Recruiting

Researchers are studying the use of depemokimab as an additional treatment for adults aged 40 to 75 with moderate to severe Chronic Obstructive Pulmonary Disorder COPD who also have type 2 inflammation. The goal is to evaluate the effectiveness and safety of starting depemokimab early alongside the standard care these patients already receive. This study is a Phase 3 trial designed to better understand how depemokimab might help reduce COPD exacerbations in this specific group. Participants will be randomly assigned to receive either depemokimab or a matching placebo, both given in combination with their existing standard treatments for COPD. The treatment period lasts up to 156 weeks about 3 years, during which the study compares the rate of moderate to severe COPD flare-ups between the two groups. This trial uses a parallel design with quadruple masking to maintain objectivity and includes ongoing standard care throughout. Throughout the study, participants will have regular evaluations to monitor their lung function, symptoms, and quality of life using questionnaires like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms E-RS for COPD. The main outcome measured is the annual rate of moderate or severe exacerbations over the study period. Safety and response to treatment will be closely observed, with follow-up continuing until the primary completion date in April 2029 and final study completion in June 2029.

Age: 40Years - 75YearsAll GendersPhase 3
121 locations
E

Actively Recruiting

Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.

Age: 18Years - 74YearsAll GendersPhase 3
205 locations